Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response

J Immunol. 2011 Apr 1;186(7):3847-57. doi: 10.4049/jimmunol.1000361. Epub 2011 Feb 23.

Abstract

We previously reported that CD8(+) T cells are directed predominantly toward the immunodominant Her-2/neu (neu) epitope RNEU(420-429) in nontolerized FVB/N but not tolerized HER-2/neu (neu-N) mice. In this study, we screened overlapping peptides of the entire neu protein and identified six new epitopes recognized by vaccine-induced neu-N-derived T cells. Evaluation of individual nondominant responses by tetramer staining and IFN-γ secretion demonstrate that this repertoire is peripherally tolerized. To address the role that the complete CD8(+) T cell repertoire plays in vaccine-induced antitumor immunity, we created a whole-cell vaccine-expressing neu cDNA that has been mutated at the RNEU(420-429) anchor residue, thereby abrogating activation of immunodominant epitope responses. Studies comparing the mutated and nonmutated vaccines indicate that nondominant CD8(+) T cells can induce antitumor immunity when combined with regulatory T cell-depleting agents in both neu-N and FVB/N mice. Collectively, these studies demonstrate that the neu-directed T cell repertoire is not intrinsically incapable of eradicating tumors. Rather, they are suppressed by mechanisms of peripheral tolerance. Thus, these studies provide new insights into the function of the complete T cell repertoire directed toward a clinically relevant tumor Ag in tumor-bearing hosts.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / pathology
  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / genetics
  • Cancer Vaccines / metabolism
  • Cell Line, Tumor
  • Dose-Response Relationship, Immunologic
  • Epitopes, T-Lymphocyte / administration & dosage
  • Epitopes, T-Lymphocyte / genetics
  • Epitopes, T-Lymphocyte / metabolism*
  • Gene Expression Regulation, Neoplastic / immunology
  • Immune Tolerance / genetics
  • Immunodominant Epitopes / administration & dosage*
  • Immunodominant Epitopes / genetics
  • Immunodominant Epitopes / metabolism
  • Lymphocyte Activation / genetics
  • Lymphocyte Activation / immunology
  • Mammary Neoplasms, Experimental / genetics
  • Mammary Neoplasms, Experimental / immunology*
  • Mammary Neoplasms, Experimental / therapy*
  • Mice
  • Mice, Transgenic
  • NIH 3T3 Cells
  • Rats
  • Receptor, ErbB-2 / deficiency*
  • Receptor, ErbB-2 / genetics
  • Receptor, ErbB-2 / metabolism

Substances

  • Cancer Vaccines
  • Epitopes, T-Lymphocyte
  • Immunodominant Epitopes
  • Receptor, ErbB-2